10 results on '"Aikawa, Naoki"'
Search Results
2. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study.
- Author
-
Aikawa N, Ishizaka A, Hirasawa H, Shimazaki S, Yamamoto Y, Sugimoto H, Shinozaki M, Taenaka N, Endo S, Ikeda T, and Kawasaki Y
- Subjects
- Acute Lung Injury physiopathology, Aged, Aged, 80 and over, Female, Glycine adverse effects, Glycine pharmacology, Humans, Infusions, Intravenous, Male, Middle Aged, Proteinase Inhibitory Proteins, Secretory adverse effects, Proteinase Inhibitory Proteins, Secretory pharmacology, Respiration, Artificial, Serine Proteinase Inhibitors adverse effects, Sulfonamides adverse effects, Survival Rate, Systemic Inflammatory Response Syndrome physiopathology, Ventilator Weaning, Acute Lung Injury drug therapy, Glycine analogs & derivatives, Serine Proteinase Inhibitors pharmacology, Sulfonamides pharmacology, Systemic Inflammatory Response Syndrome drug therapy
- Abstract
Introduction: Sivelestat, a neutrophil elastase inhibitor, has been approved in Japan for the treatment of patients with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS). The Pharmaceuticals and Medical Devices Agency (PMDA) has ordered to conduct a postmarket clinical study in order to reevaluate the efficacy and safety of Sivelestat in actual clinical settings in Japan., Methods: According to the PMDA's order, we evaluated the efficacy and safety of Sivelestat in Japanese patients with ALI associated with SIRS using ventilator-free days (VFD) as the primary endpoint. The surrogate endpoints are ventilator-weaning rate, ICU discharge rate, and 180-day survival rate. Study design was an open-label, non-randomized, multi-center clinical trial. Sivelestat was intravenously administered at 0.2 mg/kg/h continuously for a maximum of 14 days. Sivelestat group and control group were compared by adjusting the outcome values using an inverse probability of treatment weighted method based on the propensity scores., Results: Four hundred and four Sivelestat group patients and 177 control group patients were enrolled. The adjusted mean number of VFD was 15.7 and 12.1 in the Sivelestat group and control group, respectively (P = 0.0022). Both the adjusted ventilator-weaning rate and ICU discharge rate were significantly higher in the Sivelestat group than in the control group (P = 0.0028 and P = 0.019, respectively). The adjusted 180-day survival rate was significantly higher in the Sivelestat group than in the control group (71.8 percent vs. 56.3 percent)., Conclusions: Sivelestat contributed to early weaning from the mechanical ventilation, while showing no negative effect on the long-term outcomes of ALI associated with SIRS. The results of this study suggest the clinical usefulness of Sivelestat in this patient population., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
3. Neutrophil elastase and systemic inflammatory response syndrome in the initiation and development of acute lung injury among critically ill patients.
- Author
-
Fujishima S, Morisaki H, Ishizaka A, Kotake Y, Miyaki M, Yoh K, Sekine K, Sasaki J, Tasaka S, Hasegawa N, Kawai Y, Takeda J, and Aikawa N
- Subjects
- Critical Illness, Female, Fibrin analysis, Humans, Male, Middle Aged, Protein Binding, Respiratory Distress Syndrome enzymology, Respiratory Distress Syndrome mortality, alpha 1-Antitrypsin blood, Leukocyte Elastase blood, Respiratory Distress Syndrome etiology, Systemic Inflammatory Response Syndrome complications
- Abstract
Critically ill patients are commonly associated with systemic inflammatory response syndrome (SIRS) and are at a greater risk of developing acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Under these conditions, large amounts of various cytokines are produced, which either directly or indirectly induce tissue injury and finally organ dysfunctions, through the activation of neutrophils and as a result of release of cytotoxic molecules, especially neutrophil elastase (NE). In the present study, we determined plasma neutrophil elastase-alpha-1 antitrypsin complex (NE-AT) and elastase digests of cross-linked fibrin (e-XDP) in critically ill patients to elucidate the significance of NE in the initiation and progression of ALI and ARDS in the presence or absence of SIRS. We found significantly increased levels of plasma NE-AT in the patients with ARDS, especially when the definition of SIRS was met. Among ALI/ARDS groups, plasma NE-AT, but not e-XDP, correlated significantly with the decrease in PaO(2)/FIO(2) ratio and the duration of ALI/ARDS. Furthermore, NE-AT, but not e-XDP, significantly increased in subgroups whose PaO(2)/FIO(2) ratio decreased by more than 20%. Such correlations and differences between the subgroups were not observed in the non-ALI patients. From these results, we speculate that NE-AT, but not e-XDP, may be predictive of progressive lung injury in the early stage of ALI and ARDS.
- Published
- 2008
- Full Text
- View/download PDF
4. Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome.
- Author
-
Aikawa N, Fujishima S, Kobayashi M, Matsuoka S, and Abiru T
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Markov Chains, Middle Aged, Cost Savings, Glycine analogs & derivatives, Glycine therapeutic use, Health Care Costs, Respiratory Distress Syndrome drug therapy, Sulfonamides therapeutic use, Systemic Inflammatory Response Syndrome complications
- Abstract
Objectives: To conduct a cost-minimisation analysis of sivelestat sodium hydrate treatment for patients in the intensive care unit (ICU) with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS) caused by infection., Design: The analysis was performed based on data from a phase III randomised, multicentre, double-blind, controlled clinical study of up to 14 days treatment with sivelestat, in which the effect of intravenous sivelestat at a high dose (0.20 mg/kg/h; the sivelestat group) was compared with that at a low dose (0.004 mg/kg/h, effectively a placebo; the control group)., Patients: Patients with ALI associated with SIRS caused by infection, who began their treatment under mechanical ventilation management in the ICU., Methods: A four-stage Markov model was constructed to represent the possible conditions of an ALI patient: ICU plus intubated mechanical ventilation; ICU plus weaned from a mechanical ventilator; admission to the general ward; and death. The base-case analysis used a mechanical ventilator weaning daily rate of 2.9% for the control group and 4.0% for the sivelestat group, and the same mortality (1.2%) for both groups at all stages of the Markov model. Medical costs were estimated from standard fees and Japanese National Health Insurance drug prices included fees for hospitalisation within the ICU and general wards, mechanical ventilation, examinations and drug expenditure. Costs were in 2001 values. Sensitivity analyses were performed by varying the weaning rate, mortality, time between weaning and discharge to the general ward, and drug costs., Perspective: Payers of healthcare costs., Main Outcomes: The expected 30-day medical costs per patient in the control and sivelestat groups were Japanese yen (yen) 4,144,887 and 3,975,451 yen, respectively; a difference of 169,436 yen. Drug expenditure accounted for more than half of the medical costs for each group. The periods under mechanical ventilation management and in the ICU for the sivelestat group were shorter than those for the control group by 2 and 1.8 days, respectively. This was of significance in the reduction of the medical costs. A sensitivity analysis suggested that the expected costs for the sivelestat group exceeded those for the control group when the daily weaning rate for the sivelestat group was <3.5%, and also when mortality rates were set at 0.9% in the sivelestat group and 1.4% in the control group., Conclusions: This analysis suggests that from the Japanese healthcare payer perspective, treatment with sivelestat may reduce medical costs compared with standard care for patients with ALI associated with SIRS caused by infection.
- Published
- 2005
- Full Text
- View/download PDF
5. [Evaluation of severity for systemic inflammatory response syndrome and sepsis].
- Author
-
Kurihara T, Fujishima S, and Aikawa N
- Subjects
- Humans, Sepsis physiopathology, Severity of Illness Index, Systemic Inflammatory Response Syndrome physiopathology
- Abstract
Systemic inflammatory response syndrome (SIRS) is defined by four simple clinical and laboratory indices and now widely accepted for diagnosing sepsis. However, since the SIRS criteria include patients with a wide range of severity, other parameters are necessary to evaluate the severity and outcome of the patients. In this review, we discussed several methods to estimate the severity of SIRS, such as number of positive SIRS indices among four, duration of SIRS, plasma IL-6 and procalcitonin, etc.
- Published
- 2004
6. [Understanding the pathogenetic mechanisms of SIRS and sepsis and development of innovative therapies of sepsis].
- Author
-
Aikawa N and Fujishima S
- Subjects
- Humans, Sepsis drug therapy, Sepsis physiopathology, Systemic Inflammatory Response Syndrome drug therapy, Systemic Inflammatory Response Syndrome physiopathology
- Abstract
The concept of systemic inflammatory response syndrome (SIRS) was introduced in 1992 to define and objectively diagnose sepsis. Over the last decade, the definition of sepsis has been used for inclusion criteria of multicenter trials to develop innovative therapies of sepsis. With the recent understanding of the pathogenetic mechanisms of sepsis, many drugs have been tested, but only two drugs (activated protein C and neutrophil-elastase inhibitor) have been approved for clinical use in sepsis or SIRS. Further understanding of basic pathophysiology of SIRS and sepsis holds promise to develop a new therapeutic strategy to improve survival of patients with SIRS and sepsis.
- Published
- 2004
7. [Pathophysiology of hypercytokinemia].
- Author
-
Fujishima S and Aikawa N
- Subjects
- Humans, Cytokines blood, Systemic Inflammatory Response Syndrome blood
- Published
- 2004
8. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome.
- Author
-
Aikawa, Naoki and Kawasaki, Yasushi
- Abstract
Acute respiratory distress syndrome is a serious condition that can arise following direct or indirect lung injury. It is heterogeneous and has a high mortality rate. Supportive care is the mainstay of treatment and there is no definitive pharmacological treatment as yet. Sivelestat is a neutrophil elastase inhibitor approved in Japan and the Republic of Korea for acute lung injury, including acute respiratory distress syndrome in patients with systemic inflammatory response syndrome. The aim of this review is to examine the clinical utility of sivelestat in different disease states, using data from nonclinical and clinical studies. In nonclinical studies, sivelestat appears to show benefit in acute lung injury without inhibiting the host immune defense in cases of infection. Clinical studies do not yet provide a clear consensus. Phase III and IV Japanese studies have shown improvements in pulmonary function, length of intensive care unit stay, and mechanical ventilation, but a non-Japanese multicenter study did not demonstrate sivelestat to have an effect on ventilator-free days or 28-day all-cause mortality. Evidence of improvement in various parameters, including duration of stay in intensive care, mechanical ventilation, the ratio of partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FIO2 ratio) ratio, and lung injury scores, has been shown in patients with sepsis or gastric aspiration, and following the surgical treatment of esophageal cancer. To date, there are no particular concerns regarding adverse events, and the available data do not suggest that sivelestat might worsen infections. One study has analyzed cost-effectiveness, finding that sivelestat may reduce costs compared with standard care. The currently available evidence suggests that sivelestat may show some benefit in the treatment of acute lung injury/acute respiratory distress syndrome, although large, randomized controlled trials are needed in specific pathophysiological conditions to explore these potential benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Relationship between neutrophil elastase and acute lung injury in humans
- Author
-
Tamakuma, Shouetsu, Ogawa, Michio, Aikawa, Naoki, Kubota, Tatsuya, Hirasawa, Hiroyuki, Ishizaka, Akitoshi, Taenaka, Nobuyuki, Hamada, Chikuma, Matsuoka, Shozo, and Abiru, Taira
- Subjects
- *
LUNG injuries , *PATIENTS , *CLINICAL trials , *LEUCOCYTE elastase - Abstract
We conducted clinical trials in patients with acute lung injury (ALI) associated with systemic inflammatory response syndrome using a selective neutrophil elastase inhibitor, sivelestat sodium hydrate (Sivelestat), to investigate the involvement of neutrophil elastase in ALI. In the phase III double-blind study (Study 1) in 230 patients, the efficacy of Sivelestat was evaluated with the pulmonary function improvement (PFI) rating as the primary endpoint, and the weaning rate from mechanical ventilator, the discharge rate from intensive care unit (ICU), and the survival rate as secondary endpoints. Afterwards, an unblinded study (Study 2) in 20 patients was conducted using procedures for weaning from mechanical ventilation to reevaluate its efficacy with ventilator-free days (VFD) value, the primary endpoint, and to compare with that of Study 1 subgroup, which met the selection criteria used in Study 2. Sivelestat increased PFI rating, reduced duration of mechanical ventilation, and shortened stay in ICU in Study 1, although there was no significant efficacy on the survival rate. VFD value in Study 2 was comparable to that in the optimal-dose group of Study 1 subgroup, and increase in VFD value correlated with PFI rating and increase in ICU free days. It was concluded that neutrophil elastase may be involved in the pathogenesis of ALI in humans. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
10. Genetic polymorphisms in the promoter region of interleukin-8
- Author
-
Fujishima, Seitaro, Aiso, Sadakazu, Hori, Shingo, Aoki, Katsunori, and Aikawa, Naoki
- Subjects
- *
NUCLEOTIDES , *SEPSIS , *PATIENTS - Abstract
In septic patients, local and systemic production of interleukin-8 (IL-8) is augmented, and we and other researchers have previously shown that serum IL-8 levels predict the development of multiple organ dysfunction syndrome (MODS) and poor prognosis. There is a wide variation in IL-8 levels among septic patients under similar conditions and this is, at least, partly due to the genetic variability, in addition to the differences in predisposing stimuli. Thus, in the present study, we examined single nucleotide polymorphisms (SNPs), which may affect the production of IL-8. After obtaining informed consent, we draw 10 ml of heparinized blood and extracted DNA. We initially sequenced the 300-bp promoter region of the IL-8 gene in 25 Japanese healthy volunteers and confirmed one SNP at position โ251, which was identical to the previously reported SNP in Caucasians. By further analysis of IL-8 genotype by RT-PCR in 100 Japanese healthy volunteers, the genotype distribution (A/A:A/T:T/T) was 16:47:37, suggesting the similar IL-8 genotype distribution between Japanese and Caucasians. We then examined the IL-8 genotype in 10 septic patients as a preliminary study and it was 1:3:6. Additional experiments are ongoing to determine its significance. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.